PA8803401A1 - INHIBITORS OF THE NUCLEOSID BALANCE TRANSPORTER IN T1 - Google Patents

INHIBITORS OF THE NUCLEOSID BALANCE TRANSPORTER IN T1

Info

Publication number
PA8803401A1
PA8803401A1 PA20088803401A PA8803401A PA8803401A1 PA 8803401 A1 PA8803401 A1 PA 8803401A1 PA 20088803401 A PA20088803401 A PA 20088803401A PA 8803401 A PA8803401 A PA 8803401A PA 8803401 A1 PA8803401 A1 PA 8803401A1
Authority
PA
Panama
Prior art keywords
nucleosid
transporter
inhibitors
balance
ent1
Prior art date
Application number
PA20088803401A
Other languages
Spanish (es)
Inventor
Jean-Paul Rene Marie Andre Bosmans
Didier Jean-Claude Berthelot
Serge Maria Aloysius Pieters
Bie Maria Pieter Verbist
Cleyn Michel Anna Josef De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8803401A1 publication Critical patent/PA8803401A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ RELACIONADA CON NUEVOS COMPUESTOS DE FÓRMULA(I)QUE TIENEN PROPIEDADES INHIBITORIAS DEL TRANSPORTADOR EQUILIBRATIVO DE NUCLEÓSIDOS ENT1,COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS,PROCESOS QUÍMICOS PARA PREPARAR ESTOS COMPUESTOS Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES VINCULADAS CON LA INHIBICIÓN DE LOS RECEPTORES ENT1 EN LOS ANIMALES,EN PARTICULAR EN LOS SERES HUMANOS.THE PRESENT INVENTION IS RELATED TO NEW FORMULA COMPOUNDS (I) THAT HAVE INHIBITORY PROPERTIES OF THE BALANCING CARRIER OF NUCLEOSIDES ENT1, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THESE COMPOUNDS, CHEMISTRY PROCESSES IN THE COMPENSATION OF UNDERTAKINGS IN HIS COMPLEX ENT1 RECEIVERS IN ANIMALS, IN PARTICULAR IN HUMAN BEINGS.

PA20088803401A 2007-11-14 2008-11-07 INHIBITORS OF THE NUCLEOSID BALANCE TRANSPORTER IN T1 PA8803401A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07120630 2007-11-14

Publications (1)

Publication Number Publication Date
PA8803401A1 true PA8803401A1 (en) 2009-06-23

Family

ID=39145373

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088803401A PA8803401A1 (en) 2007-11-14 2008-11-07 INHIBITORS OF THE NUCLEOSID BALANCE TRANSPORTER IN T1

Country Status (18)

Country Link
US (1) US8263592B2 (en)
EP (1) EP2209790B1 (en)
JP (1) JP5369108B2 (en)
KR (1) KR101598136B1 (en)
CN (1) CN101855224B (en)
AR (1) AR069304A1 (en)
AU (1) AU2008322960B2 (en)
BR (1) BRPI0820642B1 (en)
CA (1) CA2704423C (en)
CL (1) CL2008003383A1 (en)
EA (1) EA017215B1 (en)
ES (1) ES2569511T3 (en)
HK (1) HK1146722A1 (en)
IL (1) IL205710A (en)
JO (1) JO3126B1 (en)
PA (1) PA8803401A1 (en)
TW (1) TWI437000B (en)
WO (1) WO2009062990A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201101959D0 (en) 2011-02-04 2011-03-23 Univ Nottingham Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
EP3160957B1 (en) 2014-06-26 2018-06-06 F. Hoffmann-La Roche AG Indolin-2-one or pyrrolo-pyridin-2-one derivatives
CN108137561B (en) * 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 Indolin-2-one derivatives
JP6857653B2 (en) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Indoline-2-one derivatives for use in the treatment of CNS and related disorders
MA43159B1 (en) 2015-11-06 2020-08-31 Hoffmann La Roche Indoline-2-one derivatives
CN105802999B (en) * 2016-04-01 2019-05-03 中南大学湘雅医院 A kind of kit and method of memebrane protein ENTs transmembrane transport ODNs
JP6879677B2 (en) 2016-05-26 2021-06-02 株式会社クボタ Work platform
EP3539957A4 (en) 2016-11-14 2020-05-13 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701396D0 (en) 1997-04-15 1997-04-15 Astra Pharma Prod Compounds
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
AU2003300124A1 (en) 2002-12-31 2004-07-29 BUOLAMWINI, John, K Novel nucleoside transport inhibitors
JPWO2004101593A1 (en) * 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 5'-modified nucleoside derivative and pharmaceutical use thereof
ATE537181T1 (en) * 2003-12-26 2011-12-15 Kissei Pharmaceutical BENZIMIDAZOLE DERIVATIVES AND THEIR MEDICAL USES
US8083773B2 (en) * 2005-07-15 2011-12-27 Muhammad Abubakar Atiq Durrani Apparatus for minimally invasive posterior correction of spinal deformity
TW200804393A (en) * 2005-11-14 2008-01-16 Solvay Pharm Gmbh Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use

Also Published As

Publication number Publication date
BRPI0820642A2 (en) 2020-08-11
TWI437000B (en) 2014-05-11
AR069304A1 (en) 2010-01-13
EA201070599A1 (en) 2010-12-30
CN101855224A (en) 2010-10-06
CA2704423C (en) 2017-01-10
CA2704423A1 (en) 2009-05-22
IL205710A (en) 2013-07-31
CN101855224B (en) 2012-11-28
JO3126B1 (en) 2017-09-20
ES2569511T3 (en) 2016-05-11
EP2209790B1 (en) 2016-02-17
KR101598136B1 (en) 2016-02-29
AU2008322960A1 (en) 2009-05-22
WO2009062990A3 (en) 2009-09-24
US20100280025A1 (en) 2010-11-04
CL2008003383A1 (en) 2010-02-05
JP5369108B2 (en) 2013-12-18
EA017215B1 (en) 2012-10-30
TW200936593A (en) 2009-09-01
BRPI0820642B1 (en) 2021-05-25
EP2209790A2 (en) 2010-07-28
IL205710A0 (en) 2010-11-30
WO2009062990A2 (en) 2009-05-22
HK1146722A1 (en) 2011-07-08
JP2011503147A (en) 2011-01-27
KR20100089088A (en) 2010-08-11
US8263592B2 (en) 2012-09-11
AU2008322960B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
PA8803401A1 (en) INHIBITORS OF THE NUCLEOSID BALANCE TRANSPORTER IN T1
CL2012001821A1 (en) Compounds derived from 5-alkynyl-pyrimidines, kinase inhibitors; pharmaceutical compositions containing them; and its use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2020002198A1 (en) Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors.
GT201000376A (en) ORGANIC COMPOUNDS
CR20180057A (en) NEW BICYCLE COMPOUNDS AS DUAL INHIBITORS OF ATX / CA.
CL2013002517A1 (en) Compounds derived from 5-fluoro-2'-deoxyuridine phosphoramidate; preparation procedure; pharmaceutical composition that includes them; its use in the treatment or prophylaxis of cancer.
CO6680683A2 (en) Microsomal prostaglandin e2 synthase-1 inhibitors (mpges-1) and compositions containing them, useful in the treatment of inflammatory diseases
ECSP109844A (en) SPIROCICLES AS INHIBITORS OF THE 11-BETA HYDROXIESTEROID DEHYDROGENASE TYPE 1
ECSP12012353A (en) COMPOUNDS, THIOACETATE COMPOSITIONS AND METHODS OF USE
CL2013000077A1 (en) Use of 1 ′ substituted ribose derived compounds comprising pyrrolo [1,2-f] [1,2,4] triazine nucleobases to treat paramyxoviridae infections; 1 'substituted ribose derived compounds comprising pyrrolo [1,2-f] [1,2,4] triazine nucleobases; and pharmaceutical composition that includes them.
CU20190101A7 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES
GT201000299A (en) 2,6-DIAMINO-PYRIMIDIN-5-IL-CARBOXAMIDS AS SYK OR JAK KINASAS INHIBITORS
GT200900027A (en) ORGANIC COMPOUNDS
CR20180072A (en) NEW BICYCLE COMPOUNDS AS ATX INHIBITORS
PH12012502284A1 (en) Antiviral nucleoside analogs
CL2011001967A1 (en) Compounds derived from substituted carboxamide-azaheterocyclic, p70s6k inhibitors, preparation process thereof; pharmaceutical composition that includes them; and its use in the treatment of inflammatory diseases and cancer; Pharmaceutical kit
MA33803B1 (en) BENZODIAZEPINE BROMODOMAINE INHIBITOR
ECSP11011390A (en) ESPIRO-AMIDAS SUBSTITUTED COMPOUNDS
CL2010001637A1 (en) Compounds derived from isoindolones; pharmaceutical composition comprising them; and its use as mek kinase inhibitors to treat hyperproliferative and / or inflammatory diseases such as cancer, rheumatoid arthritis among others.
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CR20180143A (en) NEW BICYCLE COMPOUNDS AS DUAL INHIBITORS OF ATX / CA
UY30220A1 (en) TETRAHYDROPIRIDOTIENOPIRIMIDINA COMPOUNDS AND METHODS FOR USE
BR112014000792A2 (en) Piperidinyl Compounds for Use as Tanquirase Inhibitors
UY33238A (en) "Compounds as bradykinin-b1 antagonists"
DOP2015000170A (en) CHEMICAL COMPOUNDS